An orally-available monovalent SMAC mimetic compound as a broad-spectrum antiviral  

作　　者：Miao Mei Maria_Antonietta Impagnatiello Jun Jiao Ulrich Reiser Ulrike Tontsch-Grunt Ju Zhang Paul Nicklin Bingke Yu Yu Wang Yuan He Xu Tan 

机构地区：[1]Tsinghua-Peking Center for Life Sciences,Beijing Advanced Innovation Center for Structural Biology,Beijing Frontier Research Center for Biological Structure,MOE Key Laboratory of Bioorganic Phosphorus Chemistry and Chemical Biology,School of Pharmaceutical Sciences,Tsinghua University,Beijing 100084,China [2]Chinese Institutes for Medical Research,Beijing 100069,China [3]Boehringer Ingelheim RCV GmbH&Co KG,Vienna,Austria [4]College of Life Sciences and Oceanography,Shenzhen University,Shenzhen 518060,China [5]Research Beyond Borders,Boehringer Ingelheim,Biberach an der Riss,Germany [6]Research Beyond Borders,Boehringer Ingelheim,Shanghai 200120,China

出　　处：《Protein & Cell》2024年第1期69-75,共7页蛋白质与细胞（英文版）

基　　金：supported by grants from the State Key Research Development Program of China to X.T. (2022Y FE0102200 and 2021YFC2300200);the Spring Breeze Fund of Tsinghua University and funding from Boehringer Ingelheim Intermational GmbH.M.M.was supported by a grant from the National Natural Science Foundation of China to M.M. (32100107);the fellowship of China Postdoctoral Science Foundation (2021M691807)。

摘　　要：DearEditor,The coronavirus disease 2019(COVID-19)pandemic caused great global morbidity and mortality concurrent with astronomical socioeconomic damages and losses.Until now,the culpable pathogen,SARS-CoV-2,has infected over 6 hundred million people resulting in more than 6 million deaths worldwide(WHO SARSCoV-2 cases).There is an urgent need for rapid development of effective and affordable therapeutics for COVID-19 patients.

关 键 词：MORTALITY spectrum COMPOUND 

分 类 号：R978.7[医药卫生—药品]